0001736865 false --12-31 2022 Q3 No Yes 0001736865 2022-01-01 2022-09-30 0001736865 2022-11-14 0001736865 2022-09-30 0001736865 2021-12-31 0001736865 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001736865 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001736865 2022-07-01 2022-09-30 0001736865 2021-07-01 2021-09-30 0001736865 2021-01-01 2021-09-30 0001736865 DVLP:PreferredStockSeriesAMember 2020-12-31 0001736865 us-gaap:CommonStockMember 2020-12-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001736865 us-gaap:RetainedEarningsMember 2020-12-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2020-12-31 0001736865 us-gaap:NoncontrollingInterestMember 2020-12-31 0001736865 2020-12-31 0001736865 DVLP:PreferredStockSeriesAMember 2021-03-31 0001736865 us-gaap:CommonStockMember 2021-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001736865 us-gaap:RetainedEarningsMember 2021-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2021-03-31 0001736865 2021-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2021-06-30 0001736865 us-gaap:CommonStockMember 2021-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001736865 us-gaap:RetainedEarningsMember 2021-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2021-06-30 0001736865 2021-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2021-12-31 0001736865 us-gaap:CommonStockMember 2021-12-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001736865 us-gaap:RetainedEarningsMember 2021-12-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-12-31 0001736865 us-gaap:NoncontrollingInterestMember 2021-12-31 0001736865 DVLP:PreferredStockSeriesAMember 2022-03-31 0001736865 us-gaap:CommonStockMember 2022-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001736865 us-gaap:RetainedEarningsMember 2022-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2022-03-31 0001736865 2022-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2022-06-30 0001736865 us-gaap:CommonStockMember 2022-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001736865 us-gaap:RetainedEarningsMember 2022-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2022-06-30 0001736865 2022-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001736865 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001736865 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-01-01 2021-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001736865 2021-01-01 2021-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2021-04-01 2021-06-30 0001736865 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001736865 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-04-01 2021-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001736865 2021-04-01 2021-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2021-07-01 2021-09-30 0001736865 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001736865 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-07-01 2021-09-30 0001736865 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001736865 DVLP:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001736865 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001736865 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-01-01 2022-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001736865 2022-01-01 2022-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2022-04-01 2022-06-30 0001736865 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001736865 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-04-01 2022-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001736865 2022-04-01 2022-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2022-07-01 2022-09-30 0001736865 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001736865 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-07-01 2022-09-30 0001736865 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001736865 DVLP:PreferredStockSeriesAMember 2021-09-30 0001736865 us-gaap:CommonStockMember 2021-09-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001736865 us-gaap:RetainedEarningsMember 2021-09-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-09-30 0001736865 us-gaap:NoncontrollingInterestMember 2021-09-30 0001736865 2021-09-30 0001736865 DVLP:PreferredStockSeriesAMember 2022-09-30 0001736865 us-gaap:CommonStockMember 2022-09-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001736865 us-gaap:RetainedEarningsMember 2022-09-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-09-30 0001736865 us-gaap:NoncontrollingInterestMember 2022-09-30 0001736865 DVLP:PuraVidaVitaminsMember 2018-07-01 0001736865 DVLP:PuraVidaVitaminsMember 2021-12-31 0001736865 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001736865 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001736865 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001736865 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001736865 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001736865 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001736865 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001736865 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001736865 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001736865 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001736865 DVLP:VendorMember DVLP:NotePayableAgreementMember 2020-12-31 0001736865 2022-09-06 0001736865 2022-09-01 2022-09-06 0001736865 DVLP:NotePayableToRelatedPartyMember 2018-05-01 2018-05-31 0001736865 DVLP:CEOMember 2021-02-01 2021-02-28 0001736865 2022-05-01 2022-05-31 0001736865 DVLP:NotePayableToRelatedPartyMember 2022-09-30 0001736865 DVLP:NotePayableToRelatedPartyMember 2021-12-31 0001736865 us-gaap:UnsecuredDebtMember 2020-01-14 0001736865 us-gaap:UnsecuredDebtMember 2020-01-13 2020-01-14 0001736865 us-gaap:UnsecuredDebtMember 2020-01-01 2020-01-14 0001736865 us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001736865 2022-01-01 2022-01-27 0001736865 DVLP:LenderMember 2022-01-01 2022-01-27 0001736865 DVLP:LenderMember 2022-01-27 0001736865 us-gaap:UnsecuredDebtMember 2022-01-27 0001736865 us-gaap:UnsecuredDebtMember 2022-01-01 2022-01-27 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-03-31 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2022-09-01 2022-09-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-09-01 2022-09-30 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2022-09-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-09-30 0001736865 2021-11-03 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-11-03 0001736865 us-gaap:DebtMember 2022-09-30 0001736865 us-gaap:DebtMember 2022-01-01 2022-09-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-11-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-11-01 2021-11-30 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2021-11-01 2021-11-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2021-11-01 2021-11-30 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2021-11-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2021-11-30 0001736865 DVLP:Debt1Member 2022-09-30 0001736865 DVLP:Debt1Member 2022-01-01 2022-09-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-03-29 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-03-02 2022-03-29 0001736865 DVLP:Debt2Member 2022-09-30 0001736865 DVLP:Debt2Member 2022-01-01 2022-09-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-04-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-04-01 2022-04-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-04-01 2022-04-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-04-30 0001736865 DVLP:Debt3Member 2022-09-30 0001736865 DVLP:Debt3Member 2022-01-01 2022-09-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-05-09 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-05-01 2022-05-09 0001736865 DVLP:Debt4Member 2022-09-30 0001736865 DVLP:Debt4Member 2022-01-01 2022-09-30 0001736865 us-gaap:MeasurementInputExpectedDividendRateMember 2022-01-01 2022-09-30 0001736865 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-01 2022-09-30 0001736865 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-01 2022-09-30 0001736865 us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-09-30 0001736865 us-gaap:MeasurementInputSharePriceMember 2022-01-01 2022-09-30 0001736865 2019-09-30 0001736865 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001736865 us-gaap:WarrantMember 2022-09-30 0001736865 us-gaap:WarrantMember 2021-12-31 0001736865 DVLP:OfficeSpaceLeaseMember 2022-09-30 0001736865 DVLP:WarehouseSpaceLeaseMember 2022-09-30 0001736865 DVLP:OfficeAndWarehouseSpaceColoradoMember 2019-12-31 0001736865 DVLP:OfficeAndWarehouseSpaceColoradoMember 2022-01-01 2022-09-30 0001736865 2020-01-01 2020-12-31 0001736865 DVLP:AssetPurchaseAndSaleAgreementMember 2022-09-01 2022-09-28 0001736865 DVLP:AssetPurchaseAndSaleAgreementMember DVLP:InventoryMember 2022-09-01 2022-09-28 0001736865 DVLP:AssetPurchaseAndSaleAgreementMember DVLP:RxDataMember 2022-09-01 2022-09-28 0001736865 DVLP:AssetPurchaseAndSaleAgreementMember us-gaap:NoncompeteAgreementsMember 2022-09-01 2022-09-28 0001736865 DVLP:OrchardTrailsMember 2022-09-23 0001736865 us-gaap:NoncompeteAgreementsMember DVLP:OrchardTrailsMember 2022-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure DVLP:Integer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended September 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Transition Period of ____________________ to ______________________

Commission file number: 000-54208

GOLDEN DEVELOPING SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada

82-2911016

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

PO Box 460573

Fort Lauderdale, FL 33346

(Address of principal executive offices) (Zip Code)

623-826-5206

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☐ NO ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at November 14, 2022
Common Stock, $.0001 par value		1,273,275,111

INDEX

		Page No.

PART I - FINANCIAL INFORMATION

ITEM 1.	CONSOLIDATED FINANCIAL STATEMENTS:	3

	Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 (unaudited)	3

	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021 (unaudited)	4

	Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the Nine Months Ended September 30, 2022 and 2021 (unaudited)	5

	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 (unaudited)	6

	Notes to Consolidated Financial Statements (unaudited)	7

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22

ITEM 4.	CONTROLS AND PROCEDURES	22

PART II - OTHER INFORMATION		21

ITEM 1.	LEGAL PROCEEDINGS	24

ITEM 1A.	RISK FACTORS	24

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	24

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	24

ITEM 4.	MINE SAFETY DISCLOSURE	24

ITEM 5.	OTHER INFORMATION	24

ITEM 6.	EXHIBITS	25

PART I — FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements.

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED BALANCE SHEETS

(Unaudited)


	September 30,			December 31,
	2022			2021

Current assets:
Cash and cash equivalents	$	339,715		$	10,735

Total current assets		339,715			10,735


Total assets	$	339,715		$	10,735

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	161,902		$	201,390
Right of use liabilities - operating leases short-term		242,001			242,001
Derivative liability		6,154			219,625
Notes payable - related party		6,117			31,317
Acquisition notes payable		50,000			50,000
Note payable		15,214			90,214
Convertible notes payable, net of debt discounts		223,366			163,609

Total current liabilities		704,754			998,156

Total liabilities		704,754			998,156

Commitments and Contingencies		–			–

Stockholders' equity:
Preferred stock, 35,000,000 shares authorized, $0.0001 par value, Series A Preferred stock, 1 share authorized, 1 issued and outstanding		–			–
Common stock, 4,000,000,000 shares authorized, $0.0001 par value, 960,775,111 and 698,127,851 issued and outstanding, respectively		96,077			69,812
Additional paid-in capital		12,308,652			11,295,446
Accumulated deficit		(12,769,768	)		(12,352,679	)
Total stockholders' equity		(365,039	)		(987,421	)

Total liabilities and stockholders' equity	$	339,715		$	10,735

The accompanying notes are an integral part of these unaudited consolidated financial statements

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended						Nine Months Ended
	September 30, 2022			September 30, 2021			September 30, 2022			September 30, 2021

Revenue	$	–		$	–		$	–		$	–
Cost of revenue		–			–			–			–

Gross profit		–			–			–			–

Operating Expenses:
Professional fees		16,755			24,595			141,265			45,054
General and administrative		54,423			40,257			151,288			45,970

Total operating expenses		71,178			64,852			292,553			91,024

Loss from Operations		(71,178	)		(64,852	)		(292,553	)		(91,024	)

Other Income (Expense)
Gain on settlement of liabilities		–			–			11,000			58,617
Derivative gain (loss)		13,149			(369,749	)		161,614			(452,008	)
Interest expense, net		(152,123	)		(41,772	)		(297,150	)		(105,682	)

Net Income (loss), before tax		(210,152	)		(476,373	)		(417,089	)		(590,097	)

Income tax expense		–			–			–			–

Net Income (Loss)	$	(210,152	)	$	(476,373	)	$	(417,089	)	$	(590,097	)

Net income (loss) from per share - basic	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Net income (loss) from per share - dilutive	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average shares outstanding - basic		826,891,349			571,507,751			768,307,858			563,046,213
Weighted average shares outstanding - dilutive		826,891,349			571,507,751			768,307,858			563,046,213

The accompanying notes are an integral part of these unaudited consolidated financial statements

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)


	Series A Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Golden Developing Solutions Share of Equity			Non Controlling			Total Stockholders’ Equity
	Shares		Amount		Shares		Amount		Capital		Deficit			(Deficit)			Interest			(Deficit)

Balance December 31, 2020		1	$	–		541,507,751	$	54,150	$	10,579,303	$	(11,722,355	)	$	(1,088,902	)	$	(54,256	)	$	(1,143,158	)

Common shares and warrants issued for deferred offering costs		–		–		30,000,000		3,000		37,707		–			40,707			–			40,707
Beneficial conversion feature upon issuance on convertible debt		–		–		–		–		9,293		–			9,293			–			9,293
Net loss		–		–		–		–		–		(90,837	)		(90,837	)		–			(90,837	)

Balance March 31, 2021		1		–		571,507,751		57,150		10,626,303		(11,813,192	)		(1,129,739	)		(54,256	)		(1,183,995	)

Net loss		–		–		–		–		–		(22,887	)		(22,887	)		–			(22,887	)

Balance June 30, 2021		1		–		571,507,751		57,150		10,626,303		(11,836,079	)		(1,152,626	)		(54,256	)		(1,206,882	)

Net loss		–		–		–		–		–		(476,373	)		(476,373	)		–			(476,373	)

Balance September 30, 2021		1	$	–		571,507,751	$	57,150	$	10,626,303	$	(12,312,452	)	$	(1,628,999	)	$	(54,256	)	$	(1,683,255	)



Balance December 31, 2021		1		–		698,127,851		69,812		11,295,446		(12,352,679	)		(987,421	)		–			(987,421	)

Common shares issued due to conversion of note		–		–		12,000,000		1,200		17,800		–			19,000			–			19,000
Common Shares issued for cash proceeds		–		–		12,500,000		1,250		48,750		–			50,000			–			50,000
Common shares issued for payment of services		–		–		10,200,000		1,020		18,220		–			19,240			–			19,240
Beneficial conversion feature		–		–		–		–		7,500		–			7,500			–			7,500
Settlement of derivative liability through note conversion		–		–		–		–		51,857		–			51,857			–			51,857
Net income		–		–		–		–		–		16,052			16,052						16,052

Balance March 31, 2022		1		–		732,827,851		73,282		11,439,573		(12,336,627	)		(823,772	)		–			(823,772	)

Common Shares issued for cash proceeds		–		–		47,500,000		4,750		185,250		–			190,000			–			190,000
Common shares issued for payment of services		–		–		5,000,000		500		17,500		–			18,000			–			18,000
Beneficial conversion feature		–		–		–		–		86,888		–			86,888			–			86,888
Warrants issued for deferred offering costs		–		–		–		–		10,112		–			10,112			–			10,112
Net income		–		–		–		–		–		(222,989	)		(222,989	)					(222,989	)

Balance June 30, 2022		1		–		785,327,851		78,532		11,739,323		(12,559,616	)		(741,761	)		–			(741,761	)

Common Shares issued for cash proceeds		–		–		93,750,000		9,375		365,625		–			375,000			–			375,000
Common shares issued for payment of services		–		–		81,697,260		8,170		203,704		–			211,874			–			211,874
Net income		–		–		–		–		–		(210,152	)		(210,152	)		–			(210,152	)

Balance September 30, 2022		1	$	–		960,775,111	$	96,077	$	12,308,652	$	(12,769,768	)	$	(365,039	)	$	–		$	(365,039	)

The accompanying notes are an integral part of these unaudited consolidated financial statements

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine Months Ended
	September 30, 2022			September 30, 2021

CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	(417,089	)	$	(590,097	)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:
Stock-based compensation		37,240			–
Note payable issued for services		75,000			–
Derivative (gain) loss		(161,614	)		423,197
Amortization of debt discount and deferred financing costs		179,938			58,036
Interest expense from derivative liability in excess of principal		67,140			28,811
Gain on settlement of debt		(11,000	)		(58,617	)
Net Changes in:
Accounts payable and accrued expenses		15,065			88,843
Net cash used in operating activities		(215,320	)		(49,827	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on notes payable		(75,000	)		–
Payments on related party loans		(25,200	)		–
Proceeds from convertible notes payable		29,500			50,000
Net proceeds from the sale of common shares		615,000			–
Net cash provided by financing activities		544,300			50,000

NET CHANGE IN CASH AND CASH EQUIVALENTS		328,980			173

CASH AND CASH EQUIVALENTS, beginning of period		10,735			–

CASH AND CASH EQUIVALENTS, end of period	$	339,715		$	173

Supplemental disclosures:
Cash paid for income taxes	$	–		$	–
Cash paid for interest	$	–		$	–

Noncash activities
Beneficial conversion feature upon issuance of convertible notes	$	94,388		$	9,293
Common stock and warrants issued for deferred financing costs	$	10,112		$	40,707
Settlement of debt paid directly by related party	$	–		$	25,200
Conversion and settlement of note	$	230,874		$	–
Settlement of derivative liability on conversion	$	51,857		$	–

The accompanying notes are an integral part of these unaudited consolidated financial statements

GOLDEN DEVELOPING SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business. Golden Developing Solutions, Inc. (the “Company” or “GDS”) was organized as a corporation in Nevada in 1998 as American Associates Group. In 2007 the name was changed to Clean Hydrogen Producers, Ltd before being changed in April of 2017 to Golden Developing Solutions, Inc. The Company has structured itself in 2022 as a pharmaceutical retail holding company and intends to make additional acquisitions in the industry in the near future.

Basis of Presentation. The accompanying unaudited financial statements of Golden Developing Solutions, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, the financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the condensed financial statements not misleading. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the final results that may be expected for the year ended December 31, 2022. For more complete financial information, these unaudited financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2021. Notes to the consolidated financial statements which would substantially duplicate the disclosures contained in the annual financial statements for the most recent fiscal period have been omitted.

Use of Estimates in Financial Statement Preparation. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation. The Company prepares its consolidated financial statements on the accrual basis of accounting. The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all of which have a fiscal year end of December 31. All intercompany accounts, balances and transactions have been eliminated in the consolidation. The Company also consolidates any variable interest entities for which the Company is the primary beneficiary based on whether the Company has the ability to direct the activities that most significantly impact the entities economic performance.

On April 27, 2018, the Company incorporated Pura Vida Vitamins, LLC as a wholly owned subsidiary. Pura Vida Vitamins, LLC entered into two consulting agreements with individuals that paid each consultant $6,000 per month in cash, additional bonuses depending on certain sales-related milestones, and 20,500,000 shares each for the completion of certain sales-related milestones, of which none were earned by either consultant. On July 1, 2018, the Company reorganized the entity to be a joint venture in which it owns 50%, in exchange for the cancelation of these consulting agreements. During the year ended December 31, 2021 the Company wrote off the balances for the non-controlling interest investment due to the dissolution of the joint venture, resulting in a loss of $53,442.

On September 26, 2018, the Company incorporated Tasos Media LLC as a wholly owned subsidiary.

On December 1, 2021, the Company incorporated Renown Pharmaceuticals LLC as a wholly owned subsidiary in the state Florida. In July 2022, the domicile was move to Delaware.

On September 30, 2022, the Company incorporated Orchard Trails, LLC as a wholly-owned subsidiary in the state of Delaware.

Goodwill, Intangible Assets, and Long-Lived Assets. Goodwill is carried at cost and is not amortized. The Company tests goodwill for impairment on an annual basis, relying on a number of factors including operating results, business plans, economic projections, anticipated future cash flows and marketplace data. Company management uses its judgment in assessing whether goodwill has become impaired between annual impairment tests according to specifications set forth in ASC 350.

The fair value of the Company’s reporting unit is dependent upon the Company’s estimate of future cash flows and other factors. The Company’s estimates of future cash flows include assumptions concerning future operating performance and economic conditions and may differ from actual future cash flows. Estimated future cash flows are adjusted by an appropriate discount rate derived from the Company’s market capitalization plus a suitable control premium at date of the evaluation.

The financial and credit market volatility directly impacts the Company’s fair value measurement through the Company’s weighted average cost of capital that the Company uses to determine its discount rate and through the Company’s stock price that the Company uses to determine its market capitalization. Therefore, changes in the stock price may also affect the amount of impairment recorded.

The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.

The Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset.

Fair Value of Financial Instruments

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the use of inputs used in valuation methodologies into the following three levels:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs which reflect a reporting entity’s own assumptions about the assumptions that market participants would use for pricing an asset or liability. For example, level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

The following table summarizes fair value measurements by level at September 30, 2022 and December 31, 2021, measured at fair value on a recurring basis:


September 30, 2022	Level 1		Level 2		Level 3		Total
Assets
None	$	–	$	–	$	–	$	–

Liabilities
Derivative liabilities	$	–	$	–	$	6,154	$	6,154

December 31, 2021	Level 1		Level 2		Level 3		Total
Assets
None	$	–	$	–	$	–	$	–

Liabilities
Derivative liabilities	$	–	$	–	$	219,625	$	219,625

The recorded amounts of financial instruments, including cash equivalents, investments, accounts payable, accrued expenses, note payable and loan from related parties approximate their market values as of September 30, 2022 and December 31, 2021 due to the intended short-term maturities of these financial instruments.

Derivative Financial Instruments

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. The Company’s policy is to evaluate for reclassification contracts with the earliest maturity date first.

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

Selling, General and Administrative Expenses. Selling, general and administrative expenses include advertising and promotional costs and research and development costs. Also included in Selling, general and administrative expenses are share-based compensation, certain warehousing fees, non-manufacturing overhead, personnel and related expenses, rent on operating leases, and professional fees.

Stock-Based Compensation. The Company applies Topic 718 “Share-Based Payments” (“Topic 718”) to share-based compensation, which requires the measurement of the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award. Compensation cost is recognized when the event occurs. The Black-Scholes option-pricing model is used to estimate the fair value of options granted.

The Company accounts for equity-based transactions with non-employees under the provisions of ASC Topic No. 505-50, “Equity-Based Payments to Non-Employees” (“Topic No. 505-50”). Topic No. 505-50 establishes that equity-based payment transactions with non-employees shall be measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

Earnings (Loss) Per Share. The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share.” ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.

During the three and nine months ended September 30, 2022, the impact of 41,064,815 warrants to purchase common stock and 122,442,534 shares issuable under convertible debt were excluded from the calculation above as their impact would be anti-dilutive. During the three and nine months ended September 30, 2021, the impact of 25,000,000 warrants to purchase common stock and 90,759,744 shares issuable under convertible debt were excluded from the calculation as their impact would be anti-dilutive.

Recently Issued Accounting Standards.

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

NOTE 2 - GOING CONCERN AND LIQUIDITY

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company had incurred substantial losses from inception to date, the Company had a working capital deficit. These factors gave rise to substantial doubt that the Company would continue as a going concern. As of September 30, 2022, the Company had $339,715 of cash and no revenue to meets its ongoing operating expenses, and liabilities of $704,754 all of which are due within 12 months, and as of September 30, 2022, the Company still had a working capital deficit. Accordingly, the substantial doubt of the Company’s ability to continue as a going concern that existed at December 31, 2021 was not alleviated and is still outstanding at September 30, 2022 and up through the date of this report.

The financial statements for the nine months ended September 30, 2022 and 2021 have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company anticipates future losses in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and, or, obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with loans or contributions from related parties and, or, the sale of common stock. There is no assurance that this series of events will be satisfactorily completed.

Financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that may be necessary if the Company is unable to continue as a going concern.

NOTE 3 - DEBT

Notes Payable

During 2020, the Company entered into a note payable agreement with a vendor related to $75,000 of accounts payable. The note bears interest at 10% per annum and is due on demand. On September 6, 2022, the Company entered into an agreement with the lender to settle the note and accrued interest of $8,486 in exchange for 16,697,260 common shares.

Notes Payable related party

In May of 2018, the Company issued a $70,025 Note payable to a related party for cash proceeds received. The related party also paid $2,000 of expense on behalf of the Company. The note was unsecured, with no stated interest rate and is due on demand. In February 2021, the CEO of the Company paid $25,200 on behalf of the Company to settle the balance of the line of credit in full. The note was unsecured, with no stated interest rate and is due on demand. In May 2022, the Company repaid the 25,200 to the related party. As of September 30, 2022 and December 31, 2021, the Company owed $6,117 and 31,317, respectively, on this note payable.

Convertible Debt

On January 14, 2020, the Company entered into an unsecured convertible promissory note, with a principal amount of $40,000. The Company received net cash proceeds of $37,000 after payment of fees of $3,000. The convertible note bears interest at 10% and matures on January 14, 2021, with interest accruing at a rate of 22% if the Company is in default. Beginning six months after the issuance of the note, the holder may convert the note at any time through the maturity date into shares of common stock, to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. The conversion price is determined based on 61% of the lowest trading price during the 20 trading days prior to the conversion date. During the year ended December 31, 2020, the Company was in default of the agreement and incurred an additional $20,000 of principal, which was recorded as interest expense. The Company also recognized $37,956 of derivative loss associated with the additional principal.

On January 27, 2022, the Company entered into a settlement agreement with the lender related to the convertible promissory note dated January 14, 2020. Pursuant to the agreement the company issued 2,000,000 shares of common stock for the conversion of $4,000 of principal balance of the note and has agreed to repay the remaining balance of $45,000 in nine equal payments of $5,000, beginning on February 1, 2022. The settlement agreement resulted in the forgiveness of $11,000 in principal on the note. The Company issued an additional 10,000,000 shares to this lender in March 2022 for the conversion of $15,000 of principal. As of September 30, 2022 the Company owed $5,000 on this note.

The Company evaluated the embedded conversion feature within the above convertible promissory note under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does meets the definition of a liability on the date the note became convertible. The Company accounted for the intrinsic value of Conversion Feature inherent to the convertible promissory note and a total debt discount of $39,131 was recorded along with a day one derivative loss of $21,558. Unamortized debt discount costs were $0 as September 30, 2022 related to this convertible note.

In March 2021, the Company entered into a Senior Secured convertible promissory note for an aggregate principal amount of $588,235. The note had an original issue discount of $88,235, bears interest at the greater of Prime plus 8% or 14%. The cash proceeds are to be distributed in tranches, with the first tranche of $65,000 being advanced in March 2021, with $15,000 of the amount paying legal fees related to the note payable and $11,471 of the original issue discount was assigned to this tranche. Each tranche has a maturity date of 9 months from the date of funding of that tranche. The principal and accrued interest are convertible into shares of the Company’s common stock at a fixed price of $0.002. In the event of default, the conversion price will be 60% of the lowest intraday rice during the previous 21 days from conversion. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. The holder of these notes is not permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion.

In connection with promissory note, the Company issued 30,000,000 shares of stock to the lender as a deferred finance cost and granted a warrant to purchase 25,000,000 shares of common stock at a fixed price of $0.006 for a period of 10 years. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. Each additional tranche that is borrowed, the Company will issue shares of common stock in the amount of 393 multiplied by the principal amount advanced, and additional warrants for 327 multiplied by the principal amount advanced. The lender will receive an additional 25,000,000 warrants upon fully funding the convertible note payable. The common stock was valued at $0.004 per share for a total fair value of 120,000 and a relative fair value of $22,304, which was recorded as a debt discount. The warrants were valued using the Black-Scholes model with volatility, measurement date Treasury yield curve rate of ten-year bond, closing stock price, convertible period, and conversion price as inputs. The fair value of the warrants was determined to be $99,014, with a relative fair value of $18,403, which was recorded to debt discount.

On November 3, 2021 the second trance in the amount of $50,000 was advanced under the March 21, 2021 financing, with $8,824 of the original issue discount being assigned to this tranche. No additional shares or warrants have been issued related to this tranche.

During the nine months ended September 30, 2022, as a result of default provisions, and additional $61,440 of principal was added to the note and recorded as interest expense. In addition, the Company issued 65,000,000 shares for the conversion of $124,688 of principal and accrued interest on the note

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $58,824 was recorded on the note.

As of September 30, 2022, the company owed $120,113 under the promissory note. Unamortized debt discount was $0 as of September 30, 2022, with $46,326 of amortization of debt discount during the nine months ended September 30, 2022.

In November 2021, the Company entered into a Secured convertible promissory note for an aggregate principal amount of $58,889. The Company received net cash proceeds of $46,500 after an original issue discount of $8,889 and legal fees of $3,500. The convertible note bears interest at 12% and matures on May 16, 2022, with interest accruing at a rate of 24% if the Company is in default. The principal and accrued interest are convertible into shares of the Company’s common stock at a fixed price of $0.002 in the event of default. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price.

In connection with promissory note, the Company issued 20,000,000 shares of stock to the lender as a deferred finance cost and granted a warrant to purchase 9,814,815 shares of common stock at a fixed price of $0.006 for a period of 5 years. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. The common stock was valued at $0.0042 per share for a total fair value of 84,000 and a relative fair value of $23,019, which was recorded as a debt discount. The warrants were valued using the Black-Scholes model with volatility, measurement date Treasury yield curve rate of ten-year bond, closing stock price, convertible period, and conversion price as inputs. The fair value of the warrants was determined to be $39,187, with a relative fair value of $10,739, which was recorded to debt discount.

As of September 30, 2022, the company owed $8,889 under the promissory note. Unamortized debt discount was $0 as of September 30, 2022, with $44,248 of amortization of debt discount during the nine months ended September 30, 2022.

On March 29, 2022, the Company entered into a secured convertible promissory note, with a principal amount of $7,500. The convertible note bears interest at 14% and matures on March 29, 2023, with interest accruing at a rate of 22% if the Company is in default. The holder may convert the note at a rate of $0.001 at any time through the maturity date into shares of common stock, to the extent and provided that no holder of this note was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. In the event of a default by the Company under the terms of the note, the conversion price will be 60% of the lowest trading price of the Company’s common stock with the previous 21 days.

As of September 30, 2022, the company owed $7,500 under the promissory note. Unamortized debt discount was $3,699 as of September 30, 2022, with $3,801 of amortization of debt discount during the nine months ended September 30, 2022.

In April 2022, the Company entered into a Secured convertible promissory note for an aggregate principal amount of $27,778. The Company received net cash proceeds of $22,000 after an original issue discount of $2,778 and legal fees of $2,500. The convertible note bears interest at 12% and matures on October 6, 2022, with interest accruing at a rate of 24% if the Company is in default. The principal and accrued interest are convertible into shares of the Company’s common stock at a fixed price of $0.001 in the event of default. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price.

In connection with promissory note, the Company granted a warrant to purchase 6,250,000 shares of common stock at a fixed price of $0.004 for a period of 5 years. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. The warrants were valued using the Black-Scholes model with volatility, measurement date Treasury yield curve rate of ten-year bond, closing stock price, convertible period, and conversion price as inputs. The fair value of the warrants was determined to be $18,714, with a relative fair value of $10,112, which was recorded to debt discount.

As of September 30, 2022, the company owed $27,778 under the promissory note. Unamortized debt discount was $911 as of September 30, 2022, with $26,867 of amortization of debt discount during the nine months ended September 30, 2022.

On May 9, 2022, the Company entered into a secured convertible promissory note, with a principal amount of $75,000 in exchange for services rendered to the Company. The convertible note bears interest at 10% and matures on November 9, 2022, with interest accruing at a rate of 22% if the Company is in default. The holder may convert the note at a rate of $0.0015 at any time through the maturity date into shares of common stock, to the extent and provided that no holder of this note was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion.

As of September 30, 2022, the company owed $75,000 under the promissory note. Unamortized debt discount was $16,304 as of September 30, 2022, with $58,696 of amortization of debt discount during the nine months ended September 30, 2022.

NOTE 4 - DERIVATIVE LIABILITIES

As discussed in Note 3 – Convertible Notes Payable, the Company analyzed the conversion features of the agreements for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion features should be classified as a derivative because the exercise price of these convertible notes are subject to a variable conversion rate. The Company has determined that the conversion feature is not considered to be solely indexed to the Company’s own stock and is therefore not afforded equity treatment. In accordance with AC 815, the Company has bifurcated the conversion feature of the notes and recorded a derivative liability.

The embedded derivatives for the notes are carried on the Company’s balance sheet at fair value. The derivative liability is marked- to-market each measurement period and any unrealized change in fair value is recorded as a component of the income statement and the associated fair value carrying amount on the balance sheet is adjusted by the change.

The fair value of the embedded derivatives for the notes were determined using the Black-Scholes option pricing model based on the following assumptions during the nine months ending September 30, 2022: (1) dividend yield of 0%, (2) expected volatility ranging from 198% - 284%, (3) risk- free interest rate ranging from 0.43% – 3.92%, (4) expected life 0.5 – 0.75 year, and (5) estimated fair value of the Company’s common stock ranging from $0.0025 - $0.0059 per share. The instruments were fair valued at the date it was settled and the period end date of September 30, 2022.

The table below presents the change in the fair value of the derivative liability:

Schedule of Derivative Liabilities
Fair value as of December 31, 2021	$	219,625
Fair value on the date of issuance recorded as debt discounts		–
Settlement of derivative upon repayment of notes		(44,452	)
Settlement of derivative upon conversion of notes		(51,857	)
Gain on change in fair value of derivatives		(117,162	)
Fair value as of September 30, 2022	$	6,154

The total impact to the Company’s statement of operations for derivatives during the nine months ended September 30, 2022 was a gain of $161,614.

NOTE 5 - STOCKHOLDERS EQUITY

In March 2019, the Board of Directors of the Company amended the Company’s articles of incorporation to increase the authorized common shares to 975,000,000. On July 17, 2019, the Board of Directors approved the below Corporate Actions and recommended to the stockholders of the Company that they approve the Corporate Actions. On July 17, 2019, a majority of the Company’s stockholders, approved the following actions:

	·	The granting of discretionary authority to the Board, at any time or times for a period of 12 months after the date of the Written Consent, to adopt an amendment to the Certificate, to effect a reverse stock split at a ratio of a minimum of 1 to 5 and a maximum of 1 to 500, such ratio to be determined by the Board, or to determine not to proceed with the reverse stock split (the “Reverse Stock Split”); and

	·	The approval of an amendment to the Certificate increasing the number of shares of Common Stock the Company is authorized to issue from 975,000,000 to 4,000,000,000 as provided for herein (the “Increase in Authorized Shares”, and together with the Reverse Stock Split, the “Corporate Actions”).

The Reverse Stock Split has not been executed to date.

During the nine months ended September 30, 2022 the company issued 153,750,000 shares of common stock for cash proceeds of $615,000

During the nine months ended September 30, 2022 the company issued 93,697,260 shares of common stock for the conversion of $230,874 of principal and interest on convertible notes as discussed in Note 3.

During the nine months ended September 30, 2022 the company issued 15,200,000 shares of common stock as compensation for services with a fair value of $37,240.

Stock Warrants

The following table represents the warrant activity for the nine months ended September 30, 2022. All warrants are accounted for as equity instruments:

Schedule of warrant activity
	Stock Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2021		34,814,815	$	0.006	$	0.006
Granted		6,250,000		0.004		0.004
Cancelled		–		–		–
Expired		–		–		–
Exercised		–		–		–
Outstanding at September 30, 2022		41,064,815	$	0.006	$	0.006
Exercisable at September 30, 2022		41,064,815	$	0.006	$	0.006

Outstanding warrants at September 30, 2022 had an aggregate intrinsic value of $11,875.

Series A Preferred Stock

During the year ended December 31, 2018 the Company sold 1 share of Series A Preferred Stock in exchange for $232,500. Each share of Series A Preferred Stock has the voting rights of 350,000,000 shares. The Series A Preferred stock has no liquidation preference, and is not entitled to any dividends paid to common stockholders.

NOTE 6 - LEASES

The Company has operating leases for its administrative offices. For purposes of calculating operating lease liabilities, lease terms may be deemed to include options to extend the lease when it is reasonably certain that the Company will exercise those options. Some leasing arrangements require variable payments that are dependent on usage, output, or may vary for other reasons, such as insurance and tax payments. The variable lease payments are not presented as part of the initial ROU asset or lease liability. The Company’s lease agreements do not contain any material restrictive covenants.

At adoption of ASC 842, the Company recognized right of use assets and liabilities for operating leases of $102,878 related to its office space lease, which has a monthly payment of $4,134 and expires in March 2021. As part of the Infusionz Acquisition, the Company assumed the business’ operating lease for warehouse space. The Company recognized preliminary estimates of the right of use assets and liabilities related of this operating lease of $23,315. The lease has a monthly payment of $4,000 through August 31, 2019. The Infusionz business also has two rental agreements with total payments of $3,800 per month with month to month terms. In April 2018, Pura Vida Vitamins LLC entered into a month to month rental agreement for office space for $1,000 per month.

During the year ended December 31, 2019, the Company entered into a real estate lease for office and warehouse space in Colorado. The lease has monthly payments ranging from approximately $19,500 to $23,700 over the lease term of 54 months. The Company has an option to acquire the leased premises at the conclusion of the lease for a purchase price of $3,500,000. Under ASC 842, this lease was determined to be an operating lease, and a right of use asset and lease liability of $928,372 was recognized at commencement of the lease. The Company did not consider the purchase option to be reasonably certain of exercise in its analysis of the lease. The Company paid a security deposit of $58,749 at commencement, along with first and last month’s rent, for a total of $102,000. During the year ended December 31, 2020, the Company was notified by its landlord to vacate the premises and lost the use of the asset. The landlord subleased the property and agreed to accept one year of payments as final settlement of the lease. The Company recognized a loss on settlement of $172,740 related to this lease.

During the year ended December 31, 2020, the Company agreed to settle an existing lease in exchange for a note payable of $15,214, which bears interest at 10% or 22% in the event of default. As of the date of this report, the Company is in default of this note. The Company recognized a loss on settlement of $6,944 related to this agreement.

The following table summarizes the lease-related assets and liabilities recorded in the consolidated balance sheet at September 30, 2022 and December 31, 2021:

Schedule of operating lease liabilities
Lease Position	September 30, 2022		December 31, 2021

Operating lease right-of-use assets	$	–	$	–
Right of use liability operating lease short term		242,001		242,001
Right of use liability operating lease long term		–		–
Total operating lease liabilities	$	242,001	$	242,001

The Company recognized operating lease cost of $0 for the nine months ended September 30, 2022 and 2021. The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable.

The following table provides the maturities of lease liabilities at September 30, 2022:


Maturity of Lease Liabilities at September 30, 2022	Operating Leases
2022	$	242,001
2023		–
2024		–
2025		–
2026		–
2027 and thereafter		–
Total future undiscounted lease payments		242,001
Less: Interest		–
Present value of lease liabilities	$	242,001

At September 30, 2022, the Company had no additional leases which had not yet commenced.

NOTE 7 - ACQUISITIONS

New Hudson Acquisition

On September 28, 2022, the Company, entered into an Asset Purchase and Sale Agreement (the “APA”) with Jai Chamunda New Hudson LLC, a Michigan limited liability company (“Seller”), pursuant to which the Company will purchase certain assets currently utilized in the operation of Seller’s pharmacy located at 56270 Grand River Ave., New Hudson, MI 48165.

The purchase price under the APA is $1,350,000, which shall include inventory of $450,000, Rx Data of $890,000 and member’s non-compete contribution of $10,000.

After closing, the Company shall engage the Seller for a period of thirty (30) days commencing from the Closing Date, no more than five (5) days a week (Monday to Friday), for a maximum of forty (40) hours per week, if necessary. The Company agrees to compensate Seller at the rate of $125.00 per hour, which payment shall be made on a bi-weekly basis upon Seller submitting an invoice to the Company.

Orchard Trails Acquisition

On September 23, 2022, Renown Pharmaceuticals LLC (“Renown”), a wholly owned subsidiary of the Company, formed in the State of Florida, entered into a Purchase Agreement (the “Purchase Agreement”) with COD Management, LLC d/b/a Orchard Trails Pharmacy (“Seller Two”), pursuant to which the Company will purchase certain assets currently utilized in the operation of Seller Two’s pharmacy located at 23133 Orchard Lake Rd. Suite 101, Farmington, MI 48336. The Company shall assume no liabilities of Seller Two.

The purchase price under the Purchase Agreement shall be established on the basis of the following assets:

	(a)	Seller Two’s salable and usable merchandise inventory at the pharmacy, which shall be valued at the original, actual cost to Seller Two;
	(b)	Non-leased furniture, fixtures, equipment, computers, transferable software, telephone numbers, and other items of a similar nature including fixtures and equipment at the pharmacy, which is valued at $10,000;
	(c)	All prescription lists, patient profiles, customer lists, prescription files, and other records relating to the pharmacy and goodwill as of the Closing Date Two, which together are valued at $255,000, and
	(d)	A covenant not to compete which will be binding upon Seller, and its officers, directors and shareholders, which is valued at $10,000.

The APA and the Purchase Agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of their respective parties.

NOTE 8 - SUBSEQUENT EVENTS

The Company evaluates subsequent events that have occurred after the balance sheet date of September 30, 2022 and up through November 14, 2022, which is the date that these financial statements are available to be issued. There are two types of subsequent events: (i) recognized, or those that provide additional evidence with respect to conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements, and (ii) non-recognized, or those that provide evidence with respect to conditions that did not exist at the date of the balance sheet but arose subsequent to that date.

On October 14, 2022, Renown and COD Management, LLC (“COD”), entered into an assignment and assumption agreement (the "Assignment and Assumption Agreement One”) with Orchard Tails, LLC, a Delaware limited liability company which is a wholly owned subsidiary of the Company (“Orchard”), to assign that certain Purchase Agreement, dated as of September 23, 2022 (the “COD Purchase Agreement”), pursuant to which Renown assigned to Orchard all of Renown’s right, title and interest in the COD Purchase Agreement, such that Orchard shall be the “Buyer” for all purposes of the COD Purchase Agreement.

The Assignment and Assumption Agreement One is joined by COD, as “Seller One”, for purposes of evidencing the agreement and consent of Seller One to the transactions set forth therein. The COD Purchase Agreement closed on October 14, 2022, on which date the Company paid COD a purchase price in the amount of $300,200. The Company will account for this transaction as a business combination under FASB ASC 805.

On October 17, 2022, the Company entered into an assignment and assumption agreement (the “Assignment and Assumption Agreement Two”) with Orchard, to assign that certain Asset Purchase and Sale Agreement, dated as of September 28, 2022 (the “Jai Chamunda Purchase Agreement”), pursuant to which the Company assigned to Orchard all of the Company’s right, title and interest in the Jai Chamunda Purchase Agreement, such that Orchard shall be the “Buyer” for all purposes of the Jai Chamunda Purchase Agreement. The Company is also party to a Distribution Agreement, dated as of September 28, 2022, which was assigned to Orchard concurrently with the Jai Chamunda Purchase Agreement.

The Assignment and Assumption Agreement Two is joined by Jai Chamunda New Hudson LLC, a Michigan limited liability company (“Jai Chamunda”), as “Seller Two”, and by SRX, LLC, a Tennessee limited liability company (“Stillwell”), in each case for purposes of evidencing the agreement and consent of Seller Two and Stillwell to the transactions set forth therein. The Company closed the APA on October 17, 2022, on which date the Company paid the seller the purchase price of $1,452,053. As of the closing, the Company began its engagement of Jai Chamunda at the rate of $125 per hour. The Company will account for this transaction as a business combination under FASB ASC 805.

On October 4, 2022, the Company entered into an Asset Purchase and Sale Agreement (the “APA One”) with Sai Siva Healthcare, LLC, a Florida limited liability company (“Seller”), pursuant to which the Company will purchase certain assets currently utilized in the operation of Seller’s pharmacy located at 12753 S.W. 42^nd St., Miami, FL 33175.

The purchase price under the APA One is $3,050,000, which shall include inventory of $650,000, RX Data of $2,390,000 and member’s non-compete contribution of $10,000. The closing of the transactions occurred on November 9, 2022, and the transaction will be accounted for as a business combination under ASC 805.

On October 4, 2022, the Company entered into a second Asset Purchase and Sale Agreement (the “APA Two”) with Bushnell Pharmacy LLC, a Florida limited liability company (“Seller Two”), pursuant to which the Company will purchase certain assets currently utilized in the operation of Seller Two’s pharmacy located at 1304 Golden Gate Drive, Southlake, TX 76092.

The purchase price under the APA Two is $2,250,000, which shall include inventory of $550,000, RX Data of $1,690,000 and member’s non-compete contribution of $10,000. The closing of the transactions occurred on November 9, 2022, and the transaction will be accounted for as a business combination under ASC 805.

The APA One and APA Two contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of their respective parties.

On October 17, 2022, the Company entered into a merchant loan with a lender for $1,469,865 and received cash proceeds of $1,425,769. The Company is required to make 44 weekly payments of $46,434 for a total repayment amount of $2,043,112.

On October 20, 2022, the Company entered into a Settlement and Exchange Agreement with Leonite Capital, LLC, pursuant to which the company agreed to issue 62,000,000 shares of common stock in full settlement of the outstanding principal and interest of $123,506

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q. The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere in this report.

Company Overview

The Company

Golden Developing Solutions, Inc. (the “Company,” “we,” “our,” or “us”) was originally incorporated on December 17, 1998 in the State of Nevada under the name American Associates Group. In 2007 the name was changed to Clean Hydrogen Producers, Ltd before being changed in April of 2017 to Golden Developing Solutions, Inc. The Company has structured itself in 2022 as a pharmaceutical retail holding company and intends to make additional acquisitions in the industry in the near future.

On September 26, 2018, the Company incorporated Tasos Media LLC as a wholly owned subsidiary.

On March 9, 2019, the Company incorporated CBD Infusionz, LLC as a wholly owned subsidiary.

On December 1, 2021, the Company incorporated Renown Pharmaceuticals LLC as a wholly owned subsidiary in the state Florida. In July 2022, the domicile was move to Delaware.

On September 30, 2022, the Company incorporated Orchard Trails, LLC as a wholly-owned subsidiary in the state of Delaware.

Operations

Golden Developing Solutions is a public online health and wellness start-up company with a focus on delivering nutritional supplements including vitamins, tinctures, softgels, and topical application products. Its pharmaceutical division specializes in providing specialty medicine with rapid delivery services and adequate medical support in the United State. The recent 4 specialty pharmacy acquisitions in 2022 have capacitated the company’s service offerings to the State of Michigan and Florida with a consolidated revenue of $100M.

We aim to position ourselves to build shareholder value by setting the highest standards in service, reliability, and safety in our rapidly growing industry.

Results of Operations

Three months ended September 30, 2022 compared to three months ended September 30, 2021

Selling, General and Administrative Expenses

Selling, general and administrative expenses amounted to $54,423 and $40,257, respectively for the three months ended September 30, 2022 and 2021, an increase of $14,166 due to increased consulting fees in the current period.

Professional fees

Professional fees amounted to $16,755 and $24,595 respectively for the three months ended September 30, 2022 and 2021. The decrease of $7,840 was due to increased investor relations along with audit and accounting related expenses to bring the Company’s reporting requirements current in the prior period.

Interest expense

Interest expense was $152,123 and $41,772 for the three months ended September 30, 2022, and 2021, respectively.

Other Income/Expense

The Company recognized gain of $13,149 for the three months ended September 30, 2022 compared to a loss of $369,749 from the change in fair value of derivative liabilities during the three months ended September 30, 2021.

Nine months ended September 30, 2022 compared to nine months ended September 30, 2021

Selling, General and Administrative Expenses

Selling, general and administrative expenses amounted to $151,288 and $45,970, respectively for the nine months ended September 30, 2022 and 2021, an increase of $105,318 due to increased consulting fees in the current period as the Company increased its operations to raise additional funds.

Professional fees

Professional fees amounted to $141,265 and $45,054 respectively for the nine months ended September 30, 2022 and 2021. The increase of $96,211 was due to increased investor relations along with audit and accounting related expenses and professional fees associated with future acquisitions.

Interest expense

Interest expense was $297,150 and $105,682 for the nine months ended September 30, 2021, and 2020, respectively.

Other Income/Expense

The Company recognized a gain of $11,000 from extinguishment of liabilities and a derivative gain of $161,614 during the nine months ended September 30, 2022, compared to a gain of $58,617 from extinguishment of liabilities and a derivative loss of $452,008 during the nine months ended September 30, 2021.

Liquidity and Capital Resources

The following is a summary of the Company’s cash flows used in operating activities for the nine months ended September 30, 2022 and 2021:

	Nine Months ended September 30, 2022			Nine Months ended September 30, 2021
Net cash used in operating activities		(215,320	)		(49,827	)
Net cash used in investing activities		–			–
Net cash provided by financing activities		544,300			50,000

Operating Activities

The cash used in operating activities from continuing operations of $215,320 for the nine months ended September 30, 2022 was primarily due working capital and general and administrative expenses during the period.

Financing Activities

The cash provided by financing activities from continuing operations of $544,300 during the nine months ended September 30, 2022 was from the proceeds of $615,000 from issuance of common shares, and $29,500 proceeds from issuance of a convertible note, offset by payments on convertible notes of $75,000 and payments on related party loans of $25,200.

We are a public company and as such we have incurred and will continue to incur significant expenses for legal, accounting and related services. As a public entity, subject to the reporting requirements of the Exchange Act of 1934, we incur ongoing expenses associated with professional fees for accounting, legal and a host of other expenses including annual reports and proxy statements, if required. We estimate that these costs will increase over the next few years and may be significantly higher if our business volume and transactional activity increases. These obligations will certainly reduce our ability and resources to expand our business plan and activities.

Going Concern

As of September 30, 2022, the Company had $339,715 of cash and had no revenue during the nine months ended September 30, 2022 to meets its ongoing operating expenses and liabilities of $704,754 all of which are due within 12 months.

Our auditor has issued a “going concern” qualification as part of its opinion in the Audit Report for the year ending December 31, 2021, and our unaudited financial statements for the quarter ended nine months ended September 30, 2022, include a “going concern” note disclosing that our ability to continue as a going concern is contingent on us being able to raise working capital to grow our operations and generate revenue.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable under the circumstances; however, actual results may vary from these estimates and assumptions.

Recently Issued Accounting Pronouncements

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Contractual Obligations

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures: Our management carried out an evaluation of the effectiveness and design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the Exchange Act). Based on that evaluation, our Chief Executive Officer and Principal Financial Officer has concluded that, at September 30, 2022, such disclosure controls and procedures were not effective due to the existing of the following material weaknesses:

●

Lack of segregation of duties. The Company did not effectively segregate certain accounting duties due to the small size of its accounting staff.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management including our Chief Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Limitations on the Effectiveness of Controls: Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Our Chief Executive Officer and Principal Financial Officer has concluded, based on his evaluation as of the end of the period covered by this Quarterly Report that our disclosure controls and procedures were not sufficiently effective to provide reasonable assurance that the objectives of our disclosure control system were met.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is not involved in any disputes and does not have any litigation matters pending. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company, threatened against or affecting our Company or our common stock, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors.

Not Applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

The Company is in default of the following debt instruments:

	-	$15,214 note payable from lease settlement bearing interest at 18%

	-	$50,000 note payable accruing interest at a default rate of 15% per year and a default rate of 15%, arising from the sale of the Infusionz Business.

	-	$5,000 convertible note payable accruing interest at a default rate of 22% per year.

	-	$120,113 convertible note payable accruing interest at a default rate of 24% per year.

	-	$8,889 convertible note payable accruing interest at a default rate of 24% per year.

Item 4. Mine Safety Disclosure.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

		Incorporated by
Exhibit		Reference		Filed or Furnished
Number	Exhibit Description	Form	Exhibit	Filing Date	Herewith
3.1	Articles of Incorporation, as amended	10-12(g)	3.1	05/01/2019
3.2	Series A Certificate of Designation	10-12(g)	3.2	05/01/2019
3.3	By-laws	10-12(g)	3.3	05/01/2019
3.4	Certificate of Amendment to Amended and Restated Articles of Incorporation, dated September 13, 2018	10-12(g)/A	3.4	07/02/2019
3.5	Certificate of Amendment to Amended and Restated Articles of Incorporation, dated March 6, 2019	10-12(g)/A	3.5	07/02/2019
4.1	Form of 3% Promissory Note issued September 18, 2018, to Tyler Bartholomew, David Lindauer, Bill Anders and Brad Billman	10-12(g)	4.1	05/01/2019
4.2	Form of 3% Promissory Note issued March 8, 2019, to the Owners of Infusionz LLC	10-12(g)	4.2	05/01/2019
10.1	Binding Joint Venture Term Sheet, dated August 15, 2018, between Pura Vida Health LLC and Golden Developing Solutions, Inc.	10-12(g)/A	10.1	07/02/2019
10.2	Asset Purchase Agreement dated September 18, 2018, by and among Golden Developing Solutions, Inc. and Layer Six Media, Inc.	10-12(g)	10.2	05/01/2019
10.3	Asset Purchase Agreement dated March 8, 2019, by and between Golden Developing Solutions, Inc., Tyler Bartholomew, David Lindauer, Bill Anders and Brad Billman	10-12(g)	10.3	05/01/2019
10.4	Asset Purchase Agreement dated March 8, 2019, by and between Golden Developing Solutions, Inc. and Infusionz, LLC	10-12(g)	10.4	05/01/2019
10.5	Form of Employment Agreement entered into with David Lindauer	10-12(g)	10.5	05/01/2019
10.6	Form of Employment Agreement entered into with Tyler Bartholomew	10-12(g)	10.5	05/01/2019
10.7	Settlement Agreement by and between Golden Developing Solutions, Inc. and Pura Vida Vitamins, LLC	10-12/(g)/A	10.7	08/14/2019
21.1	List of Subsidiaries	10-12(g)	21.1	05/01/2019
31.1	Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14 and 15d-14.				X
31.2	Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a-14 and 15d-14.				X
32.1	Certification of the Company’s Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
101.INS*	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (embedded within the Inline XBRL document)

*	Filed herewith.

**	In accordance with SEC Release 33-8238, Exhibit 32.1 is furnished and not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GOLDEN DEVELOPING SOLUTIONS, INC.

Date: November 14, 2022	By:	/s/ Stavros Triant
		Chief Executive Officer

Golden Developing Solutions, Inc. 10-Q